症状性颈动脉疾病CEA术后长期抗血栓治疗:国际实践调查与指南一致性
该国际电子调查纳入356名血管外科医生,评估症状性颈动脉疾病CEA术后长期抗血栓方案。氯吡格雷单药最常用(55%),66.6%与区域指南一致;42%支持常规采用COMPASS方案,67.5%支持随机试验评估。
要点
- CEA术后长期抗血栓实践国际差异大,33.4%与区域指南不一致。
- 氯吡格雷单药占55%, aspirin单药30%,双联抗血小板11%,低剂量利伐沙班+阿司匹林4%。
- 医生更倾向在试验中评估双通路抑制(67.5%)而非常规采用(42%)。
核心结论
- 症状性颈动脉疾病CEA术后长期抗血栓实践国际差异大,常偏离区域指南。
- 外科医生对双通路抑制的常规采用意愿低于试验评估意愿,存在临床均势。
研究设计与样本
- 国际电子调查,纳入356名施行CEA的血管外科医生。
- 受访者来自英国191名、欧洲107名、澳大拉西亚35名、巴西23名。
主要发现
- 氯吡格雷单药最常用(55%), aspirin单药30%,双联抗血小板11%,低剂量利伐沙班+阿司匹林4%。
- 按主要一致性定义,66.6%与区域指南一致,33.4%不一致。
- 42%支持常规采用COMPASS方案,67.5%支持随机试验评估。
- 最常见障碍为缺乏CEA特异性证据(54%),其次为出血担忧(18%)。
临床怎么用
- CEA术后长期抗血栓方案选择需考虑区域指南与患者出血风险。
- 双通路抑制不宜常规推广,可鼓励患者参与随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term antithrombotic therapy after carotid endarterectomy (CEA) for symptomatic carotid disease reduces recurrent vascular events, but the preferred regimen varies across regions, and the role of intensified strategies remains uncertain. We aimed to describe current international post-CEA antithrombotic practice, assess concordance with regional guidance, and examine willingness to adopt or formally evaluate dual pathway inhibition based on the COMPASS regimen. METHODS: We conducted an international electronic survey of practicing vascular surgeons who perform CEA. Respondents were asked about their routine long-term antithrombotic regimen after CEA for symptomatic carotid disease in patients without atrial fibrillation, their attitudes to low-dose rivaroxaban plus aspirin in routine practice and within a randomized trial, perceived barriers to adoption, and estimated annual recruitment capacity. Guideline concordance was assessed using prespecified regional rules. RESULTS: A total of 356 vascular surgeons responded, including 191 from the United Kingdom, 107 from Europe, 35 from Australasia, and 23 from Brazil. Clopidogrel monotherapy was the most commonly reported regimen (55%), followed by aspirin monotherapy (30%), dual antiplatelet therapy (11%), and low-dose rivaroxaban plus aspirin (4%). Using the primary concordance definition, 66.6% of responses aligned with regional guidance and 33.4% were discordant. Routine adoption of the COMPASS regimen was supported by 42% of respondents, whereas 67.5% supported evaluation within a randomized trial. The most frequently cited barrier was the absence of CEA-specific evidence (54%), followed by bleeding concerns (18%). Sixty-five percent of centers estimated that they could recruit more than 10 patients annually into a relevant trial. CONCLUSION: Reported long-term antithrombotic practice after CEA for symptomatic carotid disease varies internationally and often diverges from regional guidance. Surgeons appear more willing to evaluate dual pathway inhibition in a trial than to adopt it routinely, suggesting substantial clinical equipoise. Future work should define the optimal post-CEA regimen using procedure-specific evidence.
引用
- Baker DM, Benaragama S. Long-Term Antithrombotic Therapy After Carotid Endarterectomy for Symptomatic Carotid Disease: An International Survey of Practice Patterns, Guideline Concordance and Trial Readiness for Dual Pathway Inhibition. Ann Vasc Surg. 2026. PMID: 42567311. doi:10.1016/j.avsg.2026.07.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。